Search PubMed⌕ Search

Biomedical subjects

S Akai

Publications and source records attributed to S Akai.

At least 55 records · Page 3Linked to original sources
PubMed1984

[The clinical effect of recent decline in the gastric cancer mortality rate].

The clinical effect of the recent decline in the gastric cancer mortality rate in Niigata Prefecture was studied. The age-adjusted death rate for gastric cancer has been declining from average 60.5 per 1,000,000 population during 1958-1967 to 38.6 in 1981. From our analysis of surgically treated gastric cancer patients registered between 1972-1981 in Niigata Prefecture, the age-adjusted rate of early gastric cancer increased from 4.6 per 1,000,000 population in 1972 to 11.5 in 1981. Therefore, we conclude that there was a surgical effect of 46.1% in the decline in the gastric cancer mortality rate as of 1981.

Gastrectomy↗
PubMed1983

[Current status and problems of gastric cancer in the aged].

Based on our analysis of 1) gastric cancer patients surgically treated between 1972-1980 in Niigata Prefecture, 2) mortality statistics, and 3) 381 gastric cancer patients older than 70 years operated in our hospital, we concluded that 1) The number of geriatric surgical patients with gastric cancer, especially early gastric cancer, is on the increase in Niigata Prefecture. 2) The mortality from gastric cancer has decreased markedly in 70-74 year-old patients, has declined slightly in patient ranging from 75-79 years and has increased in patients over 80 years. 3) In patients between 75-79 years and 70-74 years, surgery as almost equally safe and their long-term survival rate was similar. Our results suggest that gastric cancer patients ranging between 75-79 years should be operated as radically as younger patients.

Aged↗
PubMed1982

[Effect of levamisole hydrochloride on advanced and recurrent breast cancer--LMS randomized controlled study of a group responding to CAF (cyclophosphamide, adriamycin, and 5-FU) therapy].

The effect of levamisole HCL on advanced and recurrent breast cancer was investigated cooperatively by a randomized controlled study using envelope method. Patients with advanced and recurrent breast cancer who had showed either complete response or partial response to the previous CAF therapy (cyclophosphamide 100 mg/body/day p.o. from day 1 to 14, adriamycin 30 mg/body/day i.v. on day 1 and 8, 5-FU 500 mg/body/day i.v. on day 1 and 8) were entered in this study and divided randomly into a control group and a levamisole group. No further treatment was given to patients of the control group until they fell into progressive disease. Patients of the levamisole group were given the drug at a daily dose of 150 mg for 3 consecutive days every fortnight. Fifty-nine cases were entered in this protocol, but 9 cases of them were ruled out as exclusions or dropouts. Therefore, the number of eligible cases was 31 in the levamisole group and 19 in the control group. Both the duration of remission and the survival time were significantly (p less than 0.05) prolonged in the levamisole group compared with the control group. There was no difference in side effects between these two groups.

Antineoplastic Agents↗